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S U M M A R Y
Objectives: The differentiation between Mycobacterium abscessus subspecies abscessus (M. abscessus) and
Mycobacterium abscessus subspecies massiliense (M. massiliense) and determination of the presence of
inducible resistance to macrolide antibiotics are important factors in the management of patients with
Mycobacterium abscessus complex (MABC) infections. Unlike pulmonary MABC infections, little
information on extrapulmonary MABC infections is available.
Methods: The molecular identiﬁcation of clinical isolates was performed, and the clinical characteristics
and treatment outcomes of 20 consecutive patients with extrapulmonary MABC infections were
assessed.
Results: M. abscessus and M. massiliense each caused 10 (50%) of the cases. Eight (80%) M. abscessus isolates
that had inducible resistance to clarithromycin harbored an intact erm(41) gene of the T28 variant,
whereas two (20%) M. abscessus isolates had the C28 erm(41) variant and were susceptible to
clarithromycin. All M. massiliense isolates had a truncated erm(41) gene and were susceptible to
clarithromycin. The drug susceptibility proﬁles other than clarithromycin were similar for the M.
abscessus and M. massiliense isolates. Of the 20 patients, 17 (85%) showed a favorable outcome, including
all patients with M. massiliense infection and 70% (7/10) of patients with M. abscessus infection. Favorable
outcomes were associated with M. massiliense and M. abscessus isolates with a non-functional erm(41)
gene (p = 0.049).
Conclusions: Precise species and subspecies identiﬁcation and the determination of macrolide
susceptibility are recommended for the optimal treatment of extrapulmonary MABC infections.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pulmonary and extrapulmonary infections caused by non-
tuberculous mycobacteria (NTM) are increasingly reported world-
wide (Prevots and Marras, 2015; Stout et al., 2016). The
Mycobacterium abscessus complex (MABC) is the most important
cause of NTM infections by rapidly growing mycobacteria (Grifﬁth
et al., 2007; Floto et al., 2016). Moreover, MABC is a highly drug-* Corresponding author. Tel.: +82 2 3410 3429. Fax: +82 2 3410 3849.
E-mail address: wjkoh@skku.edu (W.-J. Koh).
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Groote, 2015; Lee et al., 2015; Ryu et al., 2016).
The guidelines of the American Thoracic Society and Infectious
Diseases Society of America recommend macrolide-based antibi-
otic therapy combined with intravenous amikacin and cefoxitin or
imipenem, based on the results of drug susceptibility testing (DST),
for the treatment of MABC infections (Grifﬁth et al., 2007).
However, the guidelines recommend different approaches for the
treatment of extrapulmonary and pulmonary MABC infections
(Grifﬁth et al., 2007). For extrapulmonary MABC infections, such as
skin, soft tissue, and bone infections, a total of 4–6 months of
antibiotic therapy with at least 2 weeks of an initial combination of
parenteral antibiotics is recommended, with a high likelihood ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
edical College from ClinicalKey.com by Elsevier on June 11, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
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regarded as a chronic, incurable infection for most patients, even
with the recommended 2–4 months of parenteral antibiotics
followed by long-term macrolide-based antibiotic therapy (Grifﬁth
et al., 2007). The exact reasons for these different treatment
outcomes are largely unknown.
Currently, MABC can be divided into three subspecies: M.
abscessus subspecies abscessus (hereafter M. abscessus), M.
abscessus subspecies massiliense (hereafter M. massiliense), and
M. abscessus subspecies bolletii (hereafter M. bolletii) (Tortoli et al.,
2016). M. abscessus is the most common pathogen, causing 45–65%
of MABC cases, followed by M. massiliense (20–55%) and M. bolletii
(1–18%); the treatment outcomes of patients with pulmonary
MABC infections differ according to the etiologic organism (Koh
et al., 2014).
The treatment response rates to macrolide-based antibiotic
therapy are much higher in patients with pulmonary M. massiliense
infections than in those with pulmonary M. abscessus infections
(Koh et al., 2011; Lyu et al., 2014; Koh et al., 2016; Koh et al., 2017).
This difference is likely due to the presence of a functional
ribosomal methyltransferase gene, erm(41), in M. abscessus that
results in inducible macrolide resistance (susceptible on day 3 but
resistant on day 14 of DST). In contrast, the erm(41) gene in M.
massiliense is non-functional due to truncation, so inducible
resistance does not occur (Nash et al., 2009; Choi et al., 2012;
Brown-Elliott et al., 2015). In addition, previous studies have
demonstrated that 7–18% of M. abscessus clinical isolates have a
T ! C polymorphism at nucleotide 28 of the erm(41) gene, which
inactivates the gene, and as these isolates are susceptible to
macrolides (Brown-Elliott et al., 2015; Bastian et al., 2011; Yoshida
et al., 2013; Lee et al., 2014; Shallom et al., 2015), macrolides can be
useful for treating M. abscessus infections caused by the
C28 sequevar (Koh et al., 2017). However, information on the
responsiveness of extrapulmonary MABC infections to macrolide
treatment and the relevance of the different sequevars is very
limited.
Because of the high cure rate compared to pulmonary
infections, it was hypothesized that a substantial proportion of
extrapulmonary MABC infections are caused by M. massiliense or
the C28 sequevar of M. abscessus. The aim of this study was to
determine the proportions of M. massiliense and the M. abscessus
C28 sequevar among extrapulmonary MABC infections and to
examine treatment outcomes of these infections based on
causative organisms.
Materials and methods
Study population
The medical records of 22 consecutive patients with extrap-
ulmonary MABC infections treated at Samsung Medical Center (a
1979-bed referral hospital in Seoul, South Korea) from October
2010 to December 2014 were identiﬁed using an electronic
database. These medical records were reviewed. After the
exclusion of two patients who were transferred to another hospital
or lost to follow-up during treatment, 20 patients were included in
the study. This retrospective study was approved by the
Institutional Review Board of Samsung Medical Center (IRB No.
2016-03-050). Informed consent was waived for the use of medical
data because patient information was anonymized and de-
identiﬁed prior to analysis.
Microbiological examination
Acid-fast bacillus (AFB) smears and cultures were performed
using standard methods, as described previously (Koh et al., 2016).Downloaded for Anonymous User (n/a) at KESLI - Yonsei University M
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reverse blot hybridization assay of the rpoB gene (REBA Myco-ID
test; YD Diagnostics, Yongin, South Korea) (Wang et al., 2014). For
precise species identiﬁcation of the isolates, multilocus sequencing
analysis of the nearly complete 16S rRNA gene, the 16S–23S rRNA
internal transcribed spacer (ITS) sequences, partial rpoB sequences,
and partial hsp65 sequences was performed (Ben Salah et al., 2008;
Frothingham and Wilson, 1993; Turenne et al., 2001; Adekambi
et al., 2003). Detection of erm(41) and mutations in the 23S rRNA
gene (rrl) was performed by PCR sequencing, as described
previously (Bastian et al., 2011; Jamal et al., 2000). DST was
performed by broth microdilution method, and Mycobacterium
peregrinum ATCC 700686 was used for quality control, in
accordance with the guidelines of the Korean Institute of
Tuberculosis (Clinical Laboratory Standards Institute, 2011). The
minimum inhibitory concentration (MIC) was deﬁned as the
lowest drug concentration capable of inhibiting visible growth of
the mycobacteria. The MIC50 and MIC90 were deﬁned as the
concentrations required to inhibit the growth of 50% and 90% of the
strains, respectively. The MIC of clarithromycin was determined on
days 3 and 14 after incubation; MABC isolates were considered
susceptible (MIC 2 mg/ml on days 3 and 14), resistant (MIC
8 mg/ml on day 3), or inducibly resistant (susceptible on day 3,
but resistant on day 14) to clarithromycin (Clinical Laboratory
Standards Institute, 2011).
Antibiotic therapy and treatment outcomes
Treatment regimens and durations for extrapulmonary MABC
infections were not standardized but were determined by the
attending physician in the institution during the study period.
Patients with mild disease received oral or topical antibiotics, such
as macrolides (clarithromycin 1000 mg/day or azithromycin
250 mg/day) and ﬂuoroquinolones (moxiﬂoxacin 400 mg/day or
ciproﬂoxacin 500 mg/day), in the outpatient clinic. Patients with
severe disease were hospitalized and received intravenous
amikacin (10–15 mg/kg/day) combined with cefoxitin (6–12 g/
day) or imipenem (2000 mg/day) for several weeks, together with
oral antibiotics. Surgical treatment was performed during antibi-
otic treatment based on discussions among the attending
physicians and surgeons. Favorable outcomes were deﬁned as
the resolution of clinical symptoms and site lesions after antibiotic
treatment and/or initial surgical treatment. Unfavorable treatment
outcomes were deﬁned as hospital readmission for the second
surgical treatment due to clinical and radiographic deterioration
during antibiotic therapy that included at least 2 weeks of
combination parenteral antibiotic therapy.
Statistical analysis
All data are presented as the median value and range for
continuous variables and as the number and percentage for
categorical variables. Data were compared using the Mann–
Whitney U-test and Kruskal–Wallis test for continuous variables
and using the Pearson Chi-square test or Fisher’s exact test for
categorical variables. A two-sided p-value of <0.05 was considered
statistically signiﬁcant for all analyses. All analyses were
performed using IBM SPSS version 23 statistical software (IBM
Corp., Armonk, NY, USA).
Results
Clinical characteristics of patients
A total of 20 patients with extrapulmonary MABC infections
were included in the study. Baseline characteristics of the patientsedical College from ClinicalKey.com by Elsevier on June 11, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
Table 1
Baseline characteristics of 20 patients with extrapulmonary MABC infections.
Characteristics Total (N = 20)
Age, years, median (range) 51 (25–76)
Female, n (%) 14 (70)
Etiologic organism, n (%)
M. abscessus 10 (50)
M. massiliense 10 (50)
Infection site, n (%)
Skin and soft tissue 7 (35)
Bone and joint 6 (30)
Ocular 7 (35)
Treatment, n (%)
Topical antibiotics alone 4 (20)
Oral antibiotics alone 6 (30)
Oral and intravenous antibiotics 10 (50)
Treatment duration, days, median (range)
Oral antibiotics 177 (14–840)
Macrolide 177 (14–840)
Quinolone 58 (10–498)
Intravenous antibiotics 27 (4–178)
Amikacin 27 (4–168)
Cefoxitin 18 (13–113)
Imipenem 16 (4–49)
MABC, Mycobacterium abscessus complex; M. abscessus,Mycobacterium abscessus
subspecies abscessus; M. massiliense, Mycobacterium abscessus subspecies massi-
liense.
S.H. Jeong et al. / International Journal of Infectious Diseases 60 (2017) 49–56 51are summarized in Table 1. There were 14 females (70%) and six
males (30%), with a median age of 51 years (range 25–76 years).
Infection sites were skin and soft tissue (n = 7, 35%), bone and joint
(n = 6, 30%), and the ocular system (n = 7, 35%) (Figure 1). There was
no patient with a disseminated infection or blood stream infection.
Most patients were previously healthy and did not have any
underlying disease or possible risk factors for extrapulmonary
MABC infection, such as anti-interferon-gamma autoantibodies.
There was one patient who had undergone a liver transplantation
and had received immunosuppressive drugs. Among the seven
patients with skin and soft tissue infections, ﬁve had a documented
history of a medical procedure such as acupuncture. All patientsTable 2
Clarithromycin susceptibility and erm(41) and rrl genotypes of clinical isolates from 20
Patient No. Isolate DST resulta erm(41
01 M. massiliense S 
02 M. massiliense S 
03 M. massiliense S 
04 M. massiliense S 
05 M. abscessus IR T28 
06 M. abscessus IR T28 
07 M. abscessus IR T28 
08 M. massiliense S 
09 M. massiliense S 
10 M. massiliense S 
11 M. abscessus S C28 
12 M. massiliense S 
13 M. abscessus S C28 
14 M. abscessus IR T28 
15 M. abscessus IR T28 
16 M. abscessus IR T28 
17 M. massiliense S 
18 M. massiliense S 
19 M. abscessus IR T28 
20 M. abscessus IR T28 
MABC, Mycobacterium abscessus complex; M. abscessus, Mycobacterium abscessus subsp
a Results of drug susceptibility testing to clarithromycin using the microdilution me
b A thymine (T) or cytosine (C) was present at nucleotide position 28 of erm(41).
c ‘Truncated’ indicates that erm(41) was truncated and non-functional due to deletion
was present (Bastian et al., 2011).
d Wild-type (WT) sequence of AA at nucleotides 2058–2059 in rrl (Escherichia coli n
Downloaded for Anonymous User (n/a) at KESLI - Yonsei University Medi
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involvement. No patient had deep, tendon, or fascia involvement.
Among the six patients with bone and joint infections, two had a
history of a medical procedure such as intra-articular steroid
injection, two patients had recently undergone joint surgery, and
two patients had a history of recent trauma. All seven patients with
an ocular infection had a history of eye surgery, such as eye implant
surgery and lacrimal tube insertion.
Genetic analyses and DST results of the MABC isolates
The genetic analyses of the MABC isolates from the 20 patients
are shown in Table 2. The etiologic organisms were M. abscessus in
10 (50%) patients and M. massiliense in 10 (50%) patients. There
were no cases of extrapulmonary infection caused by M. bolletii.
Eight M. abscessus isolates harboring an intact erm(41) gene of the
T28 sequevar (8/10, 80%) were inducibly resistant to clarithromy-
cin, whereas two M. abscessus isolates of the C28 sequevar (2/20,
20%; patients 11 and 13) were susceptible to clarithromycin. All 10
M. massiliense isolates harbored a truncated erm(41) gene and were
susceptible to clarithromycin. All 20 M. abscessus and M.
massiliense isolates were susceptible to clarithromycin on day
3 of DST and had no mutations in the 23S rRNA gene that confer
macrolide resistance (Bastian et al., 2011; Shallom et al., 2015;
Maurer et al., 2012; Mougari et al., 2016).
The MIC range and the MIC50 and MIC90 values of each
antimicrobial agent for M. abscessus and M. massiliense isolates are
shown in Table 3. Amikacin and cefoxitin showed activity against
M. abscessus, with MIC90 values of 16 mg/ml and 32 mg/ml,
respectively. Comparatively, amikacin and cefoxitin showed
activity against M. massiliense, with MIC90 values of 32 mg/ml
and 64 mg/ml, respectively. The percentage of resistant isolates in
both groups was 10% for amikacin and 0% for cefoxitin. In addition,
M. abscessus (MIC90 16 mg/ml) appeared more susceptible to
imipenem than M. massiliense (MIC90 64 mg/ml). In contrast, most
MABC isolates showed resistance to ciproﬂoxacin, moxiﬂoxacin,
and doxycycline. patients with extrapulmonary MABC infections.
) sequevarb erm(41) lengthc rrl positions 2058–2059d
Truncated WT
Truncated WT
Truncated WT
Truncated WT
Complete WT
Complete WT
Complete WT
Truncated WT
Truncated WT
Truncated WT
Complete WT
Truncated WT
Complete WT
Complete WT
Complete WT
Complete WT
Truncated WT
Truncated WT
Complete WT
Complete WT
ecies abscessus; M. massiliense, Mycobacterium abscessus subspecies massiliense.
thod. S, susceptible; IR, inducibly resistant.
s of nucleotides 64, 65, and 159–432; ‘complete’ indicates that the full-length gene
umbering system).
cal College from ClinicalKey.com by Elsevier on June 11, 2018.
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Table 3
Results of drug susceptibility testing against M. abscessus and M. massiliense.
M. abscessus (n = 10) M. massiliense (n = 10)
MICa range MIC50a MIC90a % resistantb MICa range MIC50a MIC90a % resistantb
Clarithromycin, day 3 0.5–4 0.5 2 – 0.5 0.5 0.5 –
Clarithromycin, day 14 0.5–64 32 64 80 0.5 0.5 0.5 –
Amikacin 8–64 16 16 10 8–128 16 32 10
Cefoxitin 16–32 32 32 – 16–64 32 64 –
Imipenem 2–32 4 16 10 8–64 8 64 30
Ciproﬂoxacin 4–16 16 16 100 4–16 16 16 100
Moxiﬂoxacin 2–16 8 16 90 2–16 4 8 80
Doxycycline 32 32 32 100 0.25–32 32 32 90
M. abscessus, Mycobacterium abscessus subspecies abscessus; M. massiliense, Mycobacterium abscessus subspecies massiliense.
a MIC = minimum inhibitory concentration (mg/ml); MIC50/90 = MIC required to inhibit the growth of 50% and 90% of the strains, respectively.
b Breakpoint values are referenced from the Clinical and Laboratory Standards Institute (CLSI) recommendations (clarithromycin, 8 mg/ml; amikacin, 64 mg/ml; cefoxitin,
128 mg/ml; imipenem, 32 mg/ml; ciproﬂoxacin, 4 mg/ml; moxiﬂoxacin, 4 mg/ml; doxycycline, 8 mg/ml) (Clinical Laboratory Standards Institute, 2011).
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according to etiologic organism
Among the 20 study patients, four (20%) with ocular infections
received topical antibiotics alone and the other 16 (80%) received
oral antibiotic treatment for a median duration of 177 days (range
14–840 days); 10 patients (50%) received a combination of oral and
intravenous antibiotic treatment for a median duration of 27 days
(range 4–178 days)(Table 1).
There were no differences in age, sex, or infection site between
patients with M. abscessus and M. massiliense infections (Table 4),
and no signiﬁcant differences were found between the two groups
in the proportion of patients who received oral antibiotics and/or
intravenous antibiotics. The median duration of treatment with
oral antibiotics did not differ between patients with M. abscessus
infections (177 days, range 14–840 days) and patients with M.
massiliense infections (176 days, range 30–348 days, p = 0.837). The
median duration of intravenous antibiotic treatment also did not
differ between patients with M. abscessus infections (76 days, range
4–178 days) and those with M. massiliense infections (23 days,
range 15–27 days, p = 0.476).
Comparison of clinical characteristics and treatment modalities
according to infection site
The patients with bone and joint infections were older than
those with skin and soft tissue or ocular infections (p = 0.037)
(Table 5). However, there were no differences in sex or etiologic
organism between patients with skin and soft tissue infections,
bone and joint infections, and ocular infections. All patients with
skin and soft tissue infections or bone and joint infections received
oral antibiotic treatment with or without intravenous antibiotics.Table 4
Comparison of 20 patients with extrapulmonary MABC infection according to etiologic
M. abscessus (n = 10
Age, years, median (range) 53 (25–76) 
Female, n (%) 7 (70) 
Infection site, n (%) 
Skin and soft tissue 2 (20) 
Bone and joint 3 (30) 
Ocular 5 (50) 
Treatment, n (%)
Oral antibiotics alone 1 (10) 
Oral and intravenous antibiotics 6 (60) 
Surgical treatment 9 (90) 
Treatment duration, days, median (range)
Oral antibiotics 177 (14–840) 
Intravenous antibiotics 76 (4–178) 
MABC, Mycobacterium abscessus complex; M. abscessus, Mycobacterium abscessus subsp
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intravenous antibiotics (n = 6, 100%) than were those with skin and
soft tissue infections (n = 3, 43%) or ocular infections (n = 1, 14%,
p = 0.011). The median duration of oral antibiotic treatment was
longer in patients with bone and joint infections (343 days, range
14–840 days) than in those with skin and soft tissue infections (176
days, range 62–188 days) or ocular infections (38 days, range 30–
174), although this difference was not statistically signiﬁcant
(p = 0.053).
Treatment outcomes
Of the 20 patients, 17 (85%) showed a favorable treatment
response (Table 6). The duration of treatment with intravenous
antibiotics was shorter in patients with favorable outcomes than in
those with unfavorable outcomes (median 20 days vs. 173 days,
p = 0.017). The duration of treatment with oral antibiotics was also
shorter in patients with favorable outcomes than in those with
unfavorable outcomes (median 174 days vs. 558 days), although
this was not statistically signiﬁcant (p = 0.057). All patients with M.
massiliense infection and 70% (7/10) of patients with M. abscessus
infection showed a favorable treatment response. All three
patients with an unfavorable response were infected with M.
abscessus isolates that had an intact erm(41) gene of the
T28 sequevar, whereas a favorable outcome was associated with
M. massiliense and M. abscessus isolates with a non-functional erm
(41) gene (p = 0.049).
Discussion
Extrapulmonary MABC infections are uncommon disorders
(Piersimoni and Scarparo, 2009; Kasperbauer and Huitt, 2013). organism.
) M. massiliense (n = 10) p-Value
50 (37–74) 0.853
7 (70) 1.000
0.297
5 (50)
3 (30)
2 (20)
5 (50) 0.141
4 (40) 0.371
9 (90) 1.000
176 (30–348) 0.837
23 (15–27) 0.476
ecies abscessus; M. massiliense, Mycobacterium abscessus subspecies massiliense.
edical College from ClinicalKey.com by Elsevier on June 11, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
Table 5
Comparison of 20 patients with extrapulmonary MABC infections according to infection site.
Skin and soft tissue (n = 7) Bone and joint (n = 6) Ocular (n = 7) p-Value
Age, years, median (range) 45 (30–67) 72 (41–76) 50 (25–68) 0.037
Female, n (%) 6 (86) 5 (83) 3 (43) 0.260
Causative organism, n (%) 0.297
M. abscessus 2 (29) 3 (50) 5 (71)
T28 sequevar 2 3 3
C28 sequevar 0 0 2
M. massiliense 5 (71) 3 (50) 2 (29)
Treatment, n (%)
Oral antibiotics alone 4 (57) 0 (0) 2 (29) 0.153
Oral and intravenous antibiotics 3 (43) 6 (100) 1 (14) 0.011
Surgical treatment 7 (100) 6 (100) 5 (71) 0.300
Treatment duration, days, median (range)
Oral antibiotics 176 (62–188) 343 (14–840) 38 (30–174) 0.053
Intravenous antibiotics 37 (27–114) 23 (14–178) 4a 0.229
MABC, Mycobacterium abscessus complex; M. abscessus, Mycobacterium abscessus subspecies abscessus; M. massiliense, Mycobacterium abscessus subspecies massiliense.
a Only one patient with an ocular infection received intravenous antibiotics.
Table 6
Treatment outcomes of 20 patients with extrapulmonary MABC infection.
Favorable outcome
(n = 17)
Unfavorable outcome
(n = 3)
p-Value
Age, years, median (range) 49 (25–76) 71 (51–72) 0.146
Female, n (%) 11 (65) 3 (100) 0.521
Functioning erm(41) gene, n (%) 5 (29) 3 (100) 0.049
Etiologic organism, n (%) 0.211
M. abscessus 7 (41) 3 (100)
T28 sequevar 5 (71) 3 (100)
C28 sequevar 2 (29) 0
M. massiliense 10 (59) 0
Infection site, n (%) 0.263
Skin soft tissue 6 (35) 1 (33)
Bone and joint 4 (24) 2 (67)
Ocular 7 (41) 0
Treatment, n (%)
Oral antibiotics alone 6 (35) 0 (0) 0.521
Oral and intravenous antibiotics 7 (41) 3 (100) 0.211
Surgical treatment 15 (88) 3 (100) 1.000
Treatment duration, days, median (range)
Oral antibiotics 174 (14–348) 558 (177–840) 0.057
Intravenous antibiotics 20 (4–37) 173 (114–178) 0.017
MABC, Mycobacterium abscessus complex; M. abscessus, Mycobacterium abscessus subspecies abscessus; M. massiliense, Mycobacterium abscessus subspecies massiliense.
S.H. Jeong et al. / International Journal of Infectious Diseases 60 (2017) 49–56 53Many previous studies have not differentiated the subspecies of
MABC and have included a wide range of treatment strategies
(Bodle et al., 2008; Novosad et al., 2016). This is the ﬁrst study to
comprehensively analyze the clinical characteristics and treat-
ment outcomes of patients with extrapulmonary MABC infections
according to mycobacterial characteristics, including subspecies
differentiation. In this study, half of the extrapulmonary MABC
infections were caused by M. abscessus and the other half were
caused by M. massiliense. All M. massiliense isolates were
susceptible to clarithromycin, and of the M. abscessus isolates,
20% (2/10) had the C28 variant of erm(41) and were susceptible to
clarithromycin and 80% (8/10) had the T28 variant and were
inducibly resistant to clarithromycin. Favorable treatment out-
come rates were higher in patients infected with either M.
massiliense or the M. abscessus C28 sequevar than in those infected
with the M. abscessus T28 sequevar. These results suggest that both
precise subspecies differentiation and the determination of the
presence of inducible resistance using erm(41) gene sequencing
are very important for predicting the treatment outcome in
patients with extrapulmonary MABC infections.
Among extrapulmonary NTM infections in adults, skin and soft
tissue infections are the most common (Piersimoni and Scarparo,Downloaded for Anonymous User (n/a) at KESLI - Yonsei University Med
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procedures or traumatic injuries. Rapidly growing mycobacteria,
including MABC, are the most important NTM pathogens of skin
and soft tissue infections (Kothavade et al., 2013; Lin et al., 2014);
however, many previous studies regarding MABC skin and soft
tissue infections have not differentiated between M. abscessus and
M. massiliense (Chen et al., 2011; Mudedla et al., 2015). Recently,
postsurgical and post-procedure outbreaks of skin and soft tissue
infection caused by M. abscessus or M. massiliense have occurred in
several countries (Cheng et al., 2013; Leão et al., 2010; Kim et al.,
2007; Song et al., 2012; Koh et al., 2010); patients with such MABC
infections usually recover well after several months of oral
antibiotics, including a macrolide and ﬂuoroquinolone, with or
without initial intravenous antibiotics (Song et al., 2012; Choi et al.,
2011; Jung et al., 2014).
Several outbreaks of septic arthritis caused by MABC after
medical procedures have also been reported (Jung et al., 2015; Lee
et al., 2016). The treatment response in patients with septic
arthritis due to M. massiliense was good after about 12 months of
antibiotic treatment with or without surgery (Jung et al., 2015; Lee
et al., 2016). Vertebral osteomyelitis due to NTM is usually caused
by slowly growing mycobacteria such as Mycobacterium aviumical College from ClinicalKey.com by Elsevier on June 11, 2018.
opyright ©2018. Elsevier Inc. All rights reserved.
Figure 1. Representative pictures of extrapulmonary Mycobacterium abscessus complex infections. (A) Skin and soft tissue infections caused by M. abscessus subspecies
massiliense after injection in a 37-year-old female patient. There is an erythematous nodule on the proximal thigh. (B) Knee joint and bone infections caused by M. abscessus
subspecies massiliense after needle aspiration and injection in a 57-year-old female patient. T1-weighted sagittal magnetic resonance imaging of the right knee shows
enhanced thickened synovium in the suprapatellar bursa (arrow). Additionally, there is osteomyelitis in the patella (arrow head). (C) Eye infection caused by M. abscessus
subspecies abscessus in a 54-year-old female patient with right peri-orbital swelling and pain after surgery to the lacrimal sac. The computed tomography scan shows an
enhancing soft tissue mass in the right medial canthal area of the orbit.
54 S.H. Jeong et al. / International Journal of Infectious Diseases 60 (2017) 49–56complex or Mycobacterium xenopi, whereas causation by MABC is
rare, and additionally, most previous studies have not performed
subspecies identiﬁcation (Garcia et al., 2013; Kim et al., 2016).
NTM ocular infections have increasingly been reported over the
past few decades and are typically linked to medical interventions,
trauma, and implants (Kheir et al., 2015). The most common
causative organism is Mycobacterium chelonae, with MABC
accounting for 10% of NTM ocular infections (Kheir et al., 2015).
Some patients recover fully after antibiotic treatment, whereas
others need therapeutic surgical interventions (Kheir et al., 2015),
and unlike other extrapulmonary NTM infections, NTM ocular
infections can be successfully treated with topical antibiotics
(Abshire et al., 2004).Downloaded for Anonymous User (n/a) at KESLI - Yonsei University M
For personal use only. No other uses without permissionMABC is traditionally considered to be resistant to multiple
antibiotics, and data supporting effective drugs or regimens are
very limited. However, it is unclear why extrapulmonary MABC
infections are highly likely to be cured after 4–6 months of
antibiotic therapy, whereas MABC pulmonary disease is regarded
as an incurable infection even after more than 12–24 months of
multiple-antibiotic therapy (Grifﬁth et al., 2007). The present
study clearly demonstrated that 50% (10/20) of extrapulmonary
MABC infections were caused by M. massiliense, and 20% (2/10) of
M. abscessus isolates were of the C28 sequevar and were
susceptible to clarithromycin. All 10 patients infected with M.
massiliense and two patients infected with the M. abscessus
C28 sequevar showed favorable outcomes, whereas all threeedical College from ClinicalKey.com by Elsevier on June 11, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
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with the M. abscessus T28 sequevar. Interestingly, 63% (5/8) of the
patients with the M. abscessus T28 sequevar showed favorable
outcomes despite inducible resistance of the infecting organism to
macrolides. The effect of antibiotics other than macrolides and
combined surgical intervention, as well as the low mycobacterial
burden at sites of extrapulmonary infection, might contribute to
this relatively high rate of favorable outcome in patients with
extrapulmonary MABC infections. However, in MABC pulmonary
disease, a substantial proportion (25–42%) of cases caused by the
M. abscessus T28 sequevar also achieve successful treatment
outcomes (Koh et al., 2011; Lyu et al., 2014).
There are several limitations to this study. First, the study was
conducted at a single referral center in South Korea, and, as the
proportion of M. massiliense among MABC isolates and of
clarithromycin-susceptible isolates (C28 sequevar) among M.
abscessus isolates may vary by geographic region, some of the
ﬁndings may not be generalizable. Second, treatment regimens for
extrapulmonary MABC infections were not standardized in the
institution during the study period. Third, the pathogenesis,
severity, and optimal treatment modalities could differ depending
on the site of infection in extrapulmonary MABC infections. Finally,
it was difﬁcult to compare the clinical efﬁcacy of the different
treatment regimens because the treatment regimens were non-
standardized, the number of patients was small, and the clinical
manifestations differed. Further studies with larger numbers of
patients are needed to determine the optimal antibiotic strategies
for the treatment of extrapulmonary MABC infections according to
the site of infection.
In conclusion, 50% of extrapulmonary MABC infections were
caused by M. massiliense, which is susceptible to macrolides, and
although 80% of M. abscessus isolates were inducibly resistant to
macrolides (T28 sequevar), the remaining 20% of M. abscessus
isolates were susceptible (C28 sequevar). This prevalence of
macrolide-susceptible strains may in part explain why extrap-
ulmonary MABC infections are more likely to be cured than MABC
pulmonary disease, and indeed all patients with M. massiliense and
the M. abscessus C28 sequevar showed favorable treatment
outcomes. Precise species and subspecies identiﬁcation and the
determination of macrolide susceptibility are highly recom-
mended for the optimal management of patients with extrap-
ulmonary MABC infections.
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